Eagle Health Investments LP Has $39.67 Million Position in Icon Plc $ICLR

Eagle Health Investments LP lifted its position in shares of Icon Plc (NASDAQ:ICLR) by 45.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 358,500 shares of the medical research company’s stock after purchasing an additional 111,410 shares during the period. Icon accounts for about 6.9% of Eagle Health Investments LP’s holdings, making the stock its 2nd biggest position. Eagle Health Investments LP’s holdings in Icon were worth $39,672,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ICLR. Wellington Management Group LLP increased its stake in Icon by 26.6% in the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after buying an additional 975,268 shares during the last quarter. Orbis Allan Gray Ltd grew its holdings in shares of Icon by 1.8% in the fourth quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock valued at $767,996,000 after acquiring an additional 75,843 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Icon by 9.6% in the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock valued at $684,582,000 after acquiring an additional 329,266 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Icon by 10.3% during the first quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock valued at $366,481,000 after acquiring an additional 310,236 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Icon by 8.7% during the fourth quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock worth $545,410,000 after acquiring an additional 239,808 shares during the period. 95.61% of the stock is owned by institutional investors.

Icon Stock Up 1.8%

Shares of NASDAQ ICLR opened at $168.78 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a market capitalization of $12.92 billion, a PE ratio of 30.03, a P/E/G ratio of 8.14 and a beta of 1.22. Icon Plc has a one year low of $66.57 and a one year high of $203.91. The business’s fifty day moving average price is $152.21 and its 200-day moving average price is $135.77.

Wall Street Analysts Forecast Growth

ICLR has been the subject of a number of recent analyst reports. Citigroup upped their price objective on Icon from $140.00 to $165.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Leerink Partners set a $145.00 price target on shares of Icon in a report on Thursday, May 28th. Weiss Ratings lowered shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Jefferies Financial Group restated a “buy” rating and set a $165.00 price objective on shares of Icon in a report on Friday, May 29th. Finally, Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $168.73.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.